NCT01980589: Phase 1b: Study of Carfilzomib, Cyclophosphamide and Dexamethasone in NDMM CHAMPION 2

CHAMPION 2

NCT01980589: Phase 1: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects (CHAMPION 2)

A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects (CHAMPION 2)

The primary objective was to determine the maximum tolerated dose of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed multiple myeloma.

Sponsor

Amgen

---

ClinicalTrials.gov Identifier: NCT01980589

Official Title: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects

First Posted: November 11, 2013

Click here for details on ClinicalTrials.gov

---

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

Cyclophosphamide : National Cancer Institute

Cyclophosphamide : MedlinePlus Drug Information

Cyclophosphamide IV : MedlinePlus Drug Information

---

Drug: Carfilzomib

Drug: Cyclophosphamide

Drug: Dexamethasone

---

Clin Lymphoma Myeloma Leuk;2017

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Conclusion: Carfilzomib in combination with cyclophosphamide and dexamethasone is effective and has manageable toxicity for patients with newly diagnosed MM.

Click here for details

---

Locations

United States, California

United States, Indiana

United States, Maryland

United States, New York

United States, Tennessee

United States, Texas

United States, Virginia